Extended Data Table 2 Time to event summary for PFS assessed by investigator (ITT)

From: First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study

  1. Progression free survival is defined as the time from the date of randomization to disease progression or death whichever occurs first. Patients without event (no disease progression or death) will be censored at the date of last tumor assessment; patients without post baseline tumor assessments will be censored at the date of randomization.
  2. (1) Summaries of progression-free survival (median, percentiles) are Kaplan-Meier estimates. Confidence interval for the median is calculated using the method by Brookmeyer and Crowley.
  3. (2) Stratification factors: PD-L1, ECOG Performance Status and Distant Metastatic from IWRS.
  4. (3) The exact p value is 0.0000274705.
  5. (4) Z2 is the Fleming-Harrington weighted log-rank test under the FH (0, 1).
  6. (5) Max-combo Z=max (Z1, Z2).
  7. (6) The exact p value is 0.00004882.
  8. (7) The exact p value is 0.0000177074.
  9. (8) The exact p value is 0.00003152.
  10. (9) RMST boundary, τ value, is the smallest value among the largest observed times across the treatment arm.
  11. (10) Event-free rates are estimated using the Kaplan-Meier method. Confidence interval for event-free rate is calculated using the method by Kalbfleisch and Prentice with log-log transformation.
  12. + indicates that the minimum or maximum value from censored patients.
  13. CI: Confidence Interval; PFS: progression-free survival; RMST: Restricted Mean Survival Time; SE: Standard Error.
Back to article page